趋化因子配体13在三阴性乳腺癌中的表达及临床意义

刘银凤; 袁关利; 刘佳妮; 韩猛; 吕骥; 吴梓政

doi:10.7619/jcmp.20221448

趋化因子配体13在三阴性乳腺癌中的表达及临床意义

1.
河北省秦皇岛市第一医院乳腺外科, 河北秦皇岛, 066000
2.
河北省秦皇岛市第一医院呼吸与危重症医学科, 河北秦皇岛, 066000

基金项目:

河北省秦皇岛市重点研发计划科技支撑项目 201902A129

详细信息

通讯作者:
吴梓政, E-mail: zhizheruoshuitg1@163.com

中图分类号: R737.9;R318.04
计量
- 文章访问数: 194
- HTML全文浏览量: 72
- PDF下载量: 7
出版历程
- 收稿日期: 2022-05-05
- 网络出版日期: 2022-10-23
- 刊出日期: 2022-09-22

Expression and clinical significance of CXC motif chemokine ligand 13 in triple-negative breast cancer

1.
Department of Breast Surgery, Qinhuangdao City First Hospital of Hebei Province, Qinhuangdao, Hebei, 066000
2.
Department of Respiratory and Critical Care Medicine, Qinhuangdao City First Hospital of Hebei Province, Qinhuangdao, Hebei, 066000

摘要

摘要:
目的
探讨趋化因子配体13(CXCL13)表达水平对三阴性乳腺癌(TNBC)患者总体生存期(OS)的影响，分析CXCL13与肿瘤浸润性淋巴细胞(TIL)浸润程度及常见免疫检查点表达的关系。
方法
下载癌症基因组图谱数据库中TNBC患者的转录组测序结果及临床资料数据，分析CXCL13表达与TNBC患者OS的关系。应用基因集富集分析(GSEA)软件挖掘CXCL13在TNBC中的生物学功能; 应用肿瘤免疫评估资源(TIMER)数据库分析CXCL13与TNBC中TIL浸润程度及常见免疫检查点表达量的相关性。
结果
CXCL13在TNBC中呈显著高表达(P < 0.001)，其表达量与患者OS具有显著相关性(P < 0.05)。GSEA结果显示, CXCL13在TNBC中高表达可使关键免疫相关通路活化。TIMER数据库分析显示, CXCL13与TNBC中TIL的浸润程度及常见免疫检查点程序性死亡受体1、程序性死亡受体-配体1及细胞毒性T淋巴细胞相关蛋白4的表达量呈显著正相关(P < 0.001)。
结论
CXCL13是TNBC患者预后的预测因子，或可在TNBC的免疫治疗中发挥重要作用。
- 三阴性乳腺癌 /
- 趋化因子配体13 /
- 预后 /
- 肿瘤浸润性淋巴细胞 /
- 免疫检查点
Abstract:
Objective
To explore the effect of the expression level of CXC motif chemokine ligand 13 (CXCL13) on the overall survival (OS) of patients with triple-negative breast cancer (TNBC), and to analyze the relationships of CXCL13 with infiltration degree of tumor-infiltrating lymphocytes (TIL) and the expression of common immune checkpoints.
Methods
The transcriptome sequencing results and clinical data of TNBC patients in the cancer Genome Atlas database were downloaded, and the relationship between CXCL13 expression and OS in TNBC patients was analyzed. The biological function of CXCL13 in TNBC was excavated by Gene-set Enrichment Analysis (GSEA); the Tumor Immune Estimation Resource (TIMER) database was used to analyze the correlations of the expression level of CXCL13 with TIL infiltration degree and the expression of common immune checkpoints in TNBC.
Results
CXCL13 was significantly highly expressed in TNBC (P < 0.001), and its expression level was significantly correlated with OS of patients (P < 0.05). Results of GSEA showed that the high expression of CXCL13 in TNBC was able to activate key immune-related pathways. TIMER database analysis showed that CXCL13 was significantly positively correlated with the infiltration degree of TIL and the expressions of common immune checkpoints such as programmed death receptor 1, programmed death receptor ligand 1 and cytotoxic T lymphocyte associated protein 4 at in TNBC patients (P < 0.001).
Conclusion
CXCL13 is a prognostic factor for patients with TNBC, and may play an important role in immunotherapy of TNBC.
- triple-negative breast cancer /
- CXC motif chemokine ligand 13 /
- prognosis /
- tumor-infiltrating lymphocytes /
- immune checkpoints

HTML全文

图 1 TNBC组织和正常乳腺组织中CXCL13 mRNA的表达

A: TIMER数据库分析结果, *P<0.05, **P<0.01, ***P<0.001; B: TCGA数据库分析结果。

下载: 全尺寸图片幻灯片

图 2 CXCL13 mRNA表达与TNBC患者OS的关系

A: TCGA数据库分析的OS结果; B: Kaplan-Meier plotter数据库分析的OS结果。

下载: 全尺寸图片幻灯片

图 3 GSEA分析CXCL13 mRNA表达在TNBC中的生物学功能

A: B细胞受体通路; B: T细胞受体通路; C: 抗原加工与提呈通路; D: 细胞因子及其受体相互作用通路。

下载: 全尺寸图片幻灯片

图 4 CXCL13表达与TNBC肿瘤微环境中TIL浸润及常见免疫检查点表达的相关性

A: CXCL13表达与TIL浸润的关系; B: CXCL13表达与常见免疫检查点表达的关系。

下载: 全尺寸图片幻灯片

表 1 TNBC患者CXCL13表达与临床病理资料的关系

临床病理资料	分类	n	CXCL13表达水平		χ²	P
临床病理资料	分类	n	低表达组(n=66)	高表达组(n=66)	χ²	P
年龄	≤60岁	91	46	45	0.005	0.943
	>60岁	41	20	21
肿瘤大小	≤2 cm	35	14	21	1.768	0.184
	>2 cm	97	52	45
淋巴结转移	无	84	36	48	4.161	0.041
	有	48	30	18
TNM分期	Ⅰ期	24	7	17	5.471	0.019
	其他	108	59	49

下载: 导出CSV

参考文献(19)

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	陈怡萌. 晚期三阴性乳腺癌含铂治疗的真实世界研究及疗效预测因子的探索性研究[D]. 北京: 北京协和医学院, 2021.
[3]	刘迅舟. ALDH1A3靶向小分子YD1701抑制三阴性乳腺癌转移的初步研究[D]. 重庆: 西南大学, 2020.
[4]	朱洪宇, 史志敏. 微小RNA-338-3p调控信号转导和转录激活因子1对表皮生长因子受体酪氨酸激酶抑制剂耐药肺癌细胞株PC-9/GR中程序性死亡配体1表达和细胞凋亡的影响[J]. 实用临床医药杂志, 2022, 26(4): 100-105. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL202204023.htm
[5]	TARANTINO P, ANTONARELLI G, ASCIONE L, et al. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development[J]. Expert Opin Investig Drugs, 2022, 31(6): 499-513. doi: 10.1080/13543784.2021.1972968
[6]	NAGARSHETH N, WICHA M S, ZOU W P. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy[J]. Nat Rev Immunol, 2017, 17(9): 559-572. doi: 10.1038/nri.2017.49
[7]	LACALLE R A, BLANCO R, CARMONA-RODRÍGUEZ L, et al. Chemokine receptor signaling and the hallmarks of cancer[J]. Int Rev Cell Mol Biol, 2017, 331: 181-244.
[8]	HUSSAIN M, ADAH D, TARIQ M, et al. CXCL13/CXCR5 signaling axis in cancer[J]. Life Sci, 2019, 227: 175-186. doi: 10.1016/j.lfs.2019.04.053
[9]	COSGROVE J, NOVKOVIC M, ALBRECHT S, et al. B cell zone reticular cell microenvironments shape CXCL13 gradient formation[J]. Nat Commun, 2020, 11(1): 3677. doi: 10.1038/s41467-020-17135-2
[10]	LITCHFIELD K, READING J L, PUTTICK C, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition[J]. Cell, 2021, 184(3): 596-614, e14. doi: 10.1016/j.cell.2021.01.002
[11]	LI Y X, WANG S M, LI C Q. Four-lncRNA immune prognostic signature for triple-negative breast cancer Running title: immune lncRNAs predict prognosis of TNBC[J]. Math Biosci Eng, 2021, 18(4): 3939-3956. doi: 10.3934/mbe.2021197
[12]	KEENAN T E, TOLANEY S M. Role of immunotherapy in triple-negative breast cancer[J]. J Natl Compr Canc Netw, 2020, 18(4): 479-489. doi: 10.6004/jnccn.2020.7554
[13]	李洋, 蒋立峰, 孙旭, 等. 免疫检查点抑制剂在表皮生长因子受体突变非小细胞肺癌中的研究进展[J]. 实用临床医药杂志, 2022, 26(2): 142-148. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL202202029.htm
[14]	CORTES J, CESCON D W, RUGO H S, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. doi: 10.1016/S0140-6736(20)32531-9
[15]	YARCHOAN M, HOPKINS A, JAFFEE E M. Tumor mutational burden and response rate to PD-1 inhibition[J]. N Engl J Med, 2017, 377(25): 2500-2501. doi: 10.1056/NEJMc1713444
[16]	NISHINO M, RAMAIYA N H, HATABU H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development[J]. Nat Rev Clin Oncol, 2017, 14(11): 655-668. doi: 10.1038/nrclinonc.2017.88
[17]	ZARETSKY J M, GARCIA-DIAZ A, SHIN D S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma[J]. N Engl J Med, 2016, 375(9): 819-829. doi: 10.1056/NEJMoa1604958
[18]	王红卫, 赵阳, 张帆, 等. 肿瘤浸润淋巴细胞与三阴性乳腺癌预后关系的系统评价[J]. 国际外科学杂志, 2021, 48(9): 609-617, F3.
[19]	陈碧薇. 三阴乳腺癌免疫检查点抑制剂联合化疗有效性及安全性的Meta分析[D]. 张家口: 河北北方学院, 2021.

施引文献(9)

期刊类型引用(7)

1.	周喜云. 应用血栓弹力图对于改善心脏瓣膜置换术后患者凝血功能的效果观察. 智慧健康. 2024(33): 166-169 . 百度学术
2.	张娟利，陈亚绒. 银丹心脑通软胶囊联合静脉溶栓治疗急性缺血性脑卒中患者的临床疗效观察. 血栓与止血学. 2022(02): 207-208+211 . 百度学术
3.	李沛颖，何玺玉，杨红艳，岳娇娇，黄信生. 血栓弹力图对小儿先天性心脏病术后凝血异常的应用价值. 血栓与止血学. 2022(02): 201-203+206 . 百度学术
4.	贾俊. TEG监测凝血功能对接受体外循环复杂心脏手术成人患者围术期的凝血功能的影响. 哈尔滨医药. 2022(06): 112-113 . 百度学术
5.	万玲，叶钢，胡甦，刘俊. 血栓弹力图及下肢深静脉彩超对高龄髋关节置换术患者围术期的临床价值研究. 中国医学装备. 2021(05): 105-108 . 百度学术
6.	牛文娟. 血栓弹力图在心脏瓣膜性疾病围术期护理中的应用价值. 现代诊断与治疗. 2020(07): 1167-1169 . 百度学术
7.	罗敏，吴李萍，宗莹，卿克勤，李红霞. 血栓弹力图在新生儿弥散性血管内凝血诊断中的应用价值. 国际输血及血液学杂志. 2020(04): 332-337 . 百度学术